Takeda Falls on $2.7 Billion Charge to Settle Actos Lawsuits
This article is for subscribers only.
Takeda Pharmaceutical Co. fell in Tokyo trading after saying it will take a $2.7 billion charge to resolve lawsuits over its Actos diabetes medicine.
The stock closed 2.1 percent lower at 6,157 yen, after falling as much as 5.6 percent.